

\$85 billion Market Cap grows marginally

07 July 2010 | News



Asia's Top 20 Companies by Market Capitalization

Company	Market Cap
CSL, Australia	\$14806.20 mn
China Pharmaceutical Group, China	\$6401.28 mn
Dr Reddy's Laboratories, India	\$4481.86 mn
Sun Pharma, India	\$4093.15 mn
Mindray Medical International, China	\$3682.60 mn
Cochlear, Australia	\$3527.13 mn
Cipla, India	\$3482.63 mn
Ranbaxy Laboratories, India	\$2879.37 mn
China Shineway Pharmaceutical, China	\$2573.12 mn
WuXi PharmaTech, China	\$1662.92 mn
Glenmark, India	\$1561.57 mn
GlaxoSmithKline Pharma, India	\$1393.18 mn
Jubilant Organosys, India	\$1177.00 mn

Lupin, India	\$1156.04 mn
Cadila Healthcare, India	\$913.94 mn
Simcere Pharmaceutical Group	\$706.11 mn
Biocon, India	\$697.10 mn
CK Life Sciences, China	\$646.93 mn
The United Laboratories International, China	\$639.24 mn
Sterling Bio	\$595.49 mn

**Korea Market Cap data has not been available for this year.*


BioSpectrum Asia Pacific Survey 2010 estimates the market capitalization (MCap) of the life sciences companies in the region to be \$85.46 billion at the close of the calendar year 2009. This excludes the market capitalization of the companies from Taiwan, Singapore, Korea* and some companies from China as the actual historical data was not available so extrapolation was used to arrive at the overall figure. Compared to last year the overall figure has grown only marginally. Even though the fortunes of a number of companies have taken a sharp upturn the currency fluctuations with respect to the US dollar evens out the gains.

R&D spend averages at 9.44%

Pharma gets the major share of R&D spend

With slight improvement in the economy and business, in 2009, there was a marginal increase in the R&D spend. Though the rise was not significant, it indicates that the companies in the region are keen on developing new NCEs, biosimilars and generics. China companies continue to lead the tally with over 19 percent spend on R&D. There was a slight fall in the spending from companies in India and Malaysia as against an increase from Australia, Taiwan and Singapore. Taiwan and China companies successfully raised money by listing on stock exchanges during 2009.

In terms of segments, pharma gets the major share of the R&D spending followed by MedTech and BioPharma. Though Biotech is at the bottom of the pyramid in this respect, Biotech companies across the region spent over \$320 million during the year on R&D.



**Average R&D
 spent
 region wise**
